by Aleksandar Nikolajevic | Aug 27, 2026 | Newsletter
August 2026 Newsletter Summary: New antibody approved: Clesrovimab (Enflonsia®) received EU approval in April 2026 — the third prophylactic RSV antibody after Palivizumab and Nirsevimab. Weight-independent dosing: Fixed 105 mg dose for all newborns and infants, unlike...
by Aleksandar Nikolajevic | Jul 31, 2026 | Newsletter
July 2026 Newsletter Summary: Geographic risk: Sandfly-borne phleboviruses (SFNV, SFSV, TOSV) circulate widely across the Mediterranean, including Italy, Spain, Croatia and Greece; the main transmission season runs from May to October. Travel-associated: The vector...
by Aleksandar Nikolajevic | Jun 18, 2026 | Newsletter
June 2026 Newsletter Summary: Outbreak declared PHEIC: On 17 May 2026, the WHO declared the Bundibugyo ebolavirus (BDBV) outbreak in the DRC and Uganda a Public Health Emergency of International Concern. Case counts (as of 12 June 2026): Approximately 695 confirmed...
by Aleksandar Nikolajevic | May 29, 2026 | Newsletter
May 2026 Newsletter Summary: Outbreak status: As of 20 May 2026, eleven cases (two suspected) and three deaths linked to an expedition cruise ship; additionally, 41 confirmed cases in Argentina in the first four months of 2026 Pathogen: Andes virus (family...
by Aleksandar Nikolajevic | Apr 30, 2026 | Newsletter
April 2026 Newsletter Summary: Global resurgence: Approximately 10.3 million measles infections were recorded worldwide in 2023 (+20% vs. 2022); in 2022, 136,000 deaths occurred, predominantly among young children. Vaccination gaps: Only 76% of children globally...
by Aleksandar Nikolajevic | Mar 31, 2026 | Newsletter
March 2026 Newsletter Summary: hMPV positivity rates rose from 0.6% in January to over 12% in March 2026 — a pattern typical of temperate climates in late winter and spring. The respiratory multiplex PCR panel covering hMPV is used at the institute exclusively for...
